teva report non-gaap dilut ep revenu compar
street estim respect notabl manag slightli
rais guidanc rang total revenu ebitda though resili
copaxon signific reduct spend favor manag
commentari surround gener price eros moder lost us
continu doubt surround ebitda trough look like
function concern surround extent new gener launch drive
revenu stabil gener addit copaxon gener competit
doubt surround long-term contribut new brand name ajovi vein
continu believ ebitda multipl contract real possibl reiter
underweight rate rais pt see detail
ep disc
manag cite like trough year doubt teva
character pace declin copaxon net price slow said
specter addit gener competit price resili henc margin resili
like short-liv beyond though manag sound optimist
regard potenti stabil gener higher-valu launch like gener
certainli help product launch late continu
real concern regard rel dearth truli higher-valu gener opportun
increas commodit given heavi grow presenc ex-u
competitor bottom line view extent ebitda start improv
beyond function continu aggress cost save
latest color ajovi ajovi prescript rx quarterli
dose three consecut vial-bas self-inject regard auto-injector pen
recal aimovig emgal avail present teva develop
one provid color potenti time file regard payer
landscap manag suggest spread gross net sale could
around strike us fairli gener
highli competit class heavili contract
austedo bright spot sale austedo total compar sale
commentari surround payer access gener dovetail
commentari neurocrin ingrezza rel strong without oner step
edits/prior author tardiv dyskinesia td patient gener make bulk
austedo volum recent growth split td huntington chorea
hc around favor td lastli regard develop tourett syndrom
teva note see data anoth month see phase ii/iii
data ingrezza year-end
risk includ copaxon competit gener price risk
teva leader gener neurology-focus drug
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
actual versu pjc consensu estim
note street estim
compani report factset research pjc estim
compani report pjc estim
page
million except per share itemsactualspjc estimatesstreet estimatesnorth america market non-cor tevapjc except per
note prior estim comparison may applic due pjc updat report line item
reflect slower expect eros copaxon mg/ml
consensu estim
compani report factset research pjc estim
page
million except per america market non-cor consensu incom expens net share consensu rais pt teva
new pt base price-to-earnings ep estim
discount unchang one year unchang new
pt impli ebitda versu current multipl revis estim
reflect somewhat slower pace eros copaxon bear mind teva share
mg/ml glatiram acet market prescript volum remain rang
net price resili said continu expect short-liv
phenomenon particularli expect entri addit gener one reason
believ multipl contract warrant notabl model revis includ higher
estim austedo lower estim european rest-of-world gener
better reflect teva commentari regard foreign exchang headwind temper
view regard potenti underli organ growth though believ multipl
contract warrant given state gener busi eros copaxon
uncertainti surround contribut new brand state balanc sheet
conced multipl contract unlik signific previous expect given
manag done reason good job manag margin surround gener
segment henc higher pt
page
 quarterli annual incom statement
million except ep
sale
sell gener
incom loss tax
cog product revenu
expens total revenu
sell gener administr
sell gener administr
reflect addit copaxon mg/ml gener competit
teva close acquisit anda segment earli octob reflect full quarter contribut anda
teva alter revenu report methodolog result histor may reflect pjc estim
proprietari piper jaffray novemb
current disclosur inform compani found
